Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteosarcoma: improved survival with anticoagulation and amputation.

H C Hoover, A S Ketcham, R C Millar

    Cancer
    |June 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.

    Vaccine·2001
    Same author

    Somatostatinoma of the ampulla of vater in celiac sprue.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2000
    Same author

    Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
    Same author

    Pelvic exenteration for advanced pelvic malignancy.

    Seminars in surgical oncology·1999
    Same author

    Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study.

    Diseases of the colon and rectum·1998
    Same author

    Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998

    Warfarin anticoagulation improved survival rates in osteosarcoma patients undergoing amputation. This cancer treatment strategy may prevent metastasis by inhibiting fibrin deposition around circulating tumor cells.

    Area of Science:

    • Oncology
    • Pharmacology
    • Surgical Oncology

    Background:

    • Osteosarcoma is a rare bone cancer with significant metastatic potential.
    • Amputation is a common treatment for localized osteosarcoma.
    • Experimental studies suggested anticoagulation could inhibit metastasis.

    Purpose of the Study:

    • To evaluate the efficacy of warfarin anticoagulation as an adjunct to amputation in osteosarcoma patients.
    • To determine if anticoagulation impacts patient survival rates.

    Main Methods:

    • A study involving osteosarcoma patients undergoing amputation.
    • Warfarin anticoagulation administered 7 days preoperatively, during surgery, and up to 6 months postoperatively.
    • Comparison of survival rates between anticoagulated patients and a non-anticoagulated control group.

    Related Experiment Videos

    Main Results:

    • Survival rate in the anticoagulated group was 56% (5 of 9 patients) at 5-8 years.
    • Survival rate in the non-anticoagulated control group was 14% (3 of 21 patients) at 5-11 years.
    • A statistically significant improvement in survival was observed in the anticoagulated cohort.

    Conclusions:

    • Warfarin anticoagulation as an adjunct to amputation significantly increases survival in osteosarcoma patients.
    • The mechanism may involve inhibiting fibrin deposition, reducing tumor cell adherence and metastasis.
    • This approach offers a potential strategy to improve outcomes for osteosarcoma patients.